

## **TITLE**

PrHADLIMA™

Adalimumab injection

40 mg in 0.8 mL sterile solution (50 mg/mL), pre-filled syringe for subcutaneous injection

PrHADLIMA™

Adalimumab injection

40 mg in 0.8 mL sterile solution (50 mg/mL), auto-injector for subcutaneous injection

HADLIMA™ (adalimumab injection) is a biosimilar biologic drug (biosimilar) to Humira®.

Biological Response Modifier

**HADLIMA™ or HADLIMA™ PushTouch™ (adalimumab injection) treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, adult hidradenitis suppurativa, plaque psoriasis or adult uveitis, and familiar with the HADLIMA™ or HADLIMA™ PushTouch™ efficacy and safety profile.**

## **COMPANY NAME AND ADDRESS**

SAMSUNG BIOEPIS

107, Cheomdan-daero, Yeonsu-gu, Incheon, 21987,  
Republic of Korea

Distributed by:

Merck Canada Inc.

Kirkland QC Canada H9H 4M7

**DATE OF INITIAL APPROVAL**

December 20, 2018

**DATE OF REVISION**

December 20, 2019

**CONTROL NUMBER**

123456

